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Abstract
The initial goal of this study was to investigate alterations in adenosine A2A receptor (A2AR) 
density or function in a rat model of Huntington disease (HD) with reported insensitivity to an 
A2AR antagonist. Unsuspected negative results led to the hypothesis of a low striatal adenosine 
tone and to the search for the mechanisms involved. Extracellular striatal concentrations of 
adenosine were measured with in vivo microdialysis in two rodent models of early 
neuropathological stages of HD disease, the Tg51 rat and the zQ175 knock-in mouse. In view of 
the crucial role of the equilibrative nucleoside transporter (ENT1) in determining extracellular 
content of adenosine, the binding properties of the ENT1 inhibitor [3H]-S-(4-Nitrobenzyl)-6-
thioinosine were evaluated in zQ175 mice and the differential expression and differential 
coexpression patterns of the ENT1 gene (SLC29A1) were analyzed in a large human cohort of HD 
disease and controls. Extracellular striatal levels of adenosine were significantly lower in both 
animal models as compared with control littermates and striatal ENT1 binding sites were 
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significantly upregulated in zQ175 mice. ENT1 transcript was significantly upregulated in HD 
disease patients at an early neuropathological severity stage, but not those with a higher severity 
stage, relative to non-demented controls. ENT1 transcript was differentially coexpressed (gained 
correlations) with several other genes in HD disease subjects compared to the control group. The 
present study demonstrates that ENT1 and adenosine constitute biomarkers of the initial stages of 
neurodegeneration in HD disease and also predicts that ENT1 could constitute a new therapeutic 
target to delay the progression of the disease.
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Introduction
Huntington disease (HD) is an inherited neurodegenerative disorder generally affecting 
young adults and characterized by progressive chorea, cognitive impairments and emotional 
disturbances. HD is caused by a single dominant gene mutation that is an expanded CGA 
repeat in the huntingtin (HTT) gene (The Huntington Disease Collaborative Research 
Group, 1993). The pathological hallmark of the disease is the atrophy of the striatum 
(Vonsattel et al., 1985; Ferrante et al., 1987) with considerable loss of projecting medium 
spiny neurons, but neurodegeneration in the cortex and other brain areas is also observed 
(Vonsattel et al., 1985). Among the two subtypes of medium spiny neurons, the GABAergic 
enkephalin-containing neurons, which selectively express dopamine D2 receptors (D2R) and 
adenosine A2A receptors (A2AR) (Ferré et al., 1993; Quiroz et al., 2009), are the most 
vulnerable (Mitchell et al., 1999). In fact, previous studies found a preferential decrease in 
the striatal A2AR and D2R versus dopamine D1 receptor density in the early stages of the 
disease (Glass et al., 2000). But the decrease in the density of A2AR seems to involve a 
downregulation independent of neurodegeneration, related to alterations in the normal 
regulation of transcription of the A2AR gene (Chiang et al., 2005; Villar-Menéndez et al., 
2013). A2AR is usually shown to be downregulated in early stages of neuropathological 
development in rodent models of HD and several preclinical and clinical studies have 
suggested that the decrease in A2AR density or its tonic activation could be involved in the 
pathogenesis of HD (reviewed in Lee and Chern, 2014). In fact, tonic activation of A2AR is 
necessary for the action of brain-derived neurotrophic factor (BDNF; Diogenes et al., 2004; 
Rodrigues et al., 2014), which is greatly impaired during HD progression (Zuccato et al., 
2001). Finally, genetic and epidemiological studies also support the involvement of A2AR. 
Several polymorphisms in the A2AR gene have been associated to a reduced age of onset of 
the disease (Dhaenens et al. 2009; Taherzadeh-Fard et al., 2010) and, in a recent study, 
caffeine (non-selective adenosine receptor antagonist) intake (more than 190 mg/day) was 
significantly associated with a reduced age of onset of HD by about 4 years (Simonin et al., 
2013). Apart from these findings involving specifically A2AR, diverse alterations in other 
adenosine receptor subtypes and in adenosine homeostasis have also been documented in 
animal models of HD (Lee and Chern, 2014).
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We previously reported that the A2AR antagonist KW-6002 did not induce locomotor 
activation at early neuropathological stages of HD phenotypic development in the transgenic 
rat expressing a fragment of the HTT gene with 51 CAG repeats (Tg51) (von Horsten et al., 
2003), which was interpreted as a possible alteration in A2AR density or function (Orrú et 
al., 2011). The initial aim of the present study was to investigate the type of A2AR alteration 
involved. Unexpectedly, an A2AR agonist produced similar psychomotor depressant effects 
in Tg51 rats as compared to wild-type (WT) littermate controls. Furthermore, radioligand-
binding experiments would not show any significant difference in the properties of striatal 
A2AR antagonist binding in Tg51 rats as compared to controls. The possibility of a low 
striatal adenosine tone was therefore addressed. This was demonstrated with in vivo 
microdialysis experiments both in Tg51 rats and in a more recently introduced animal model 
of HD, the zQ175 knock-in mouse, which expresses a HTT carrying 188 CAG repeats 
(Heikkinen et al., 2012; Menalled et al., 2012).
We then investigated the possibility of changes in a crucial player in the major route to 
uptake extracellular adenosine into the cells, the equilibrative nucleoside transporter ENT1, 
a protein mainly expressed by astroglial cells. The present study demonstrates that, in fact, 
ENT1 is not only upregulated in the striatum of zQ175 knock-in mice, but its gen 
(SLC29A1) is also significantly overexpressed in the brain of patients with initial 
neuropathological stages of HD and differentially coexpressed in HD patients as compared 
to the control group.
Materials and Methods
Animals and drugs
Transgenic HD rats expressing a fragment of 727 amino-acids of HTT with 51 CAG repeats 
(Tg51; initially provided by the Department of Medical Genetics, University of Tubingen, 
Germany, and bred in our Institute (von Horsten et al., 2003), and knock-in HD mice with 
constitutive HTT carrying 188 CAG repeats (zQ175) provided by CHDI Foundation; Los 
Angeles, CA; (Heikkinen et al., 2012; Menalled et al., 2012) were used. For Tg51 rats, 3- 
and 12-month old animals from three genotypes (homozygous, heterozygous and wild-type 
littermates) were used. For zQ175 mice, 12-month old animals from two genotypes 
(heterozygous and wild-type littermates) were used. The previously reported 
neuropathological changes of 12-month old hetero- and homozygous Tg51 rats (Kántor et 
al., 2006) and 12-month old heterozygous zQ175 mice (Heikkinen et al., 2012) correspond 
to grade 2 in the Vonsattel neuropathological severity score in patients with HD (see below). 
Animals were housed in pairs per cage and kept on a 12/12-dark/light cycle with food and 
water available ad libitum. All animals used in the study were maintained in accordance with 
the guidelines of National Institutes of Health animal care and the animal research approved 
by the NIDA IRP Animal Care and Use Committee (protocol #09-BNRB-73). The A2AR 
agonist CGS-21680 was kindly provided by CHDI Foundation.
Locomotor activity
Locomotor activity in rats was measured in open field soundproof chambers (50 × 50 cm, 
Med Associates Inc., VT). The rats were not habituated to the experimental cages and 
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recording of the locomotor activity started immediately after administration of the A2AR 
agonist CGS-21680, by placing the animals in the box. Locomotion was measured by 
counting the number of breaks in the infrared beams of the chamber during consecutive 
periods of min. Results were analyzed as the average of 10-min period transformed (square 
root) counts during the 90-min period of observation. All the animals were tested only once.
In vivo microdialysis
Rats and mice were anesthetized with 3 ml/kg of Equithesin (4.44 g of chloral hydrate, 
0.972 g of Na pentobarbital, 2.124 g of MgSO4, 44.4 ml of propylene glycol, 12 ml of 
ethanol and distilled H2O up to 100 ml of final solution; NIDA Pharmacy, Baltimore, MD). 
A concentric microdialysis probe with 2-mm long dialysis membranes (Eicom Corp, Tokyo, 
Japan) was implanted into the dorsolateral striatum of rats (coordinates were 0.0 mm 
anterior, 4.5 mm lateral and 7.0 mm ventral from bregma) or mice (coordinates were 1.0 mm 
anterior, 1.5 mm lateral and 4.5 ventral from bregma). In both cases, the probe was fixed to 
the skull with successive layers of glass ionomer cement (CX Plus, Shofu Dental, Japan). 
The in vivo microdialysis experiments were performed on freely moving rats and mice 24 h 
after probe implantation. An artificial cerebrospinal solution (in mM, 144 NaCl, 4.8 KCl, 1.7 
CaCl2, and 1.2 MgCl2) was pumped through the microdialysis probe at a constant rate of 1 
µl/min. After a washout period of 90 min, dialysate samples were collected at 30-min 
intervals and immediately frozen at −80°C until adenosine levels were determined. The 
adenosine content in the samples was analyzed by HPLC coupled to a fluorescence detector 
(RF-10A XL; Shimadzu Scientific Instruments, Columbia, MD) as previously reported 
(Melani et al., 1999). Adenosine was detected as a fluorescent derivative (1,N6-
ethenoadenosine) following derivatization with chloroacetaldehyde. Zinc acetate (0.14 µl, 
0.1 M) was added to each µl sample. The solution was transferred into glass vials, where 
0.18 µl of chloroacetaldehyde (4.5%) was added for each ml of solution obtained. This 
solution was kept at 100° C for 20 min. Adenosine was identified by its disappearance after 
incubation of the sample with 1U of adenosine deaminase at room temperature for 1 min. 
The minimum detectable amount of adenosine was 0.01 pmol. Standard solutions were 
arranged with Tris/HCl pH 7.4 and subjected to an identical procedure as that one of 
samples. The in vitro recovery rate of adenosine was 9.84 ± 0.81%. The concentration 
values reported were not corrected for recovery. Mean of adenosine concentrations of eight 
microdialysis samples obtained from each animal were calculated.
Radioligand-binding experiments
Striatal membrane preparations from Tg51 rats or zQ175 mice were used to analyze binding 
of the A2AR antagonist [3H] 4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-
ylamino]ethyl)phenol ([3H] ZM241385; American Radiolabelled Chemicals, St. Louis, MO) 
and the ENT1 inhibitor [3H]-S-(4-Nitrobenzyl)-6-thioinosine ([3H]NBTI; PerkinElmer, 
Boston, MA) (Choi et al., 2004). Animals were deeply anesthetized with Equithesin (see in 
vivo microdialysis subsection) and euthanized by decapitation. The brains were quickly 
removed on ice, the striatum dissected out and homogenized in 50 mM Tris-HCl buffer (pH 
7.4) containing a protease inhibitor cocktail (1:1000, Sigma, US). Membranes were obtained 
by centrifugation at 100,000 g (45 min, 4°C) and washed 2 times in the same conditions. 
Protein was quantified by the bicinchoninic acid method (Pierce, Rockford, IL). Pellets were 
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resuspended and membrane suspensions (0.2 mg of protein/ml) were incubated in 50 mM 
Tris-HCl (pH 7.4) containing 2 I.U./ml of adenosine deaminase (Roche, Basel, Switzerland) 
and increasing concentrations of the radiolabelled adenosine A2AR antagonist or the ENT1 
inhibitor. In both cases, free and membrane-bound ligand were separated by rapid filtration 
on 500 µl aliquots in a 96-well plate harvester (Brandel, Gaithersburg, MD) and washed with 
2 ml of ice-cold Tris-HCl. Non-specific binding was determined in the presence of 10 mM 
ZM241385 or 10 mM non-labeled NBTI. Filter plates were incubated with Microscint-20 
(65 µl/well) scintillation liquid (PerkinElmer), incubated overnight at RT and radioactivity 
counts were determined in a MicroBeta2 plate counter (PerkinElmer) with an efficiency of 
41%. Saturation curves were analyzed by non-linear regression using Prism 4 (GraphPad 
Software, La Jolla, CA).
Analysis of transcript levels of ENT1 in postmortem human prefrontal cortex
The relative transcript level (differential expression, DE) of the ENT1 gene (SLC29A1) in 
the postmortem prefrontal cortex of 157 non-HD subjects and 127 HD patients were derived 
from gene expression data collected in a previous study (Narayanan et al., 2014). The 
expression data was adjusted for the same covariates (such as age and gender) as in the 
previous study using the same method, robust linear regression (rlm) except for one 
difference: Instead of fitting an rlm model of each gene expression data separately for the 
AD, HD, and control groups using the covariates as in the previous study, we fit an rlm 
model of each gene expression data once using all AD, HD, and control expression values to 
ensure that the DE signal is not lost in the adjustment. Two different probes (probe 1: 5’ -
GCA CCC TGT ACA GTT GCC ACG TTA CTG CCT TTT TTA AAA ATA TAT TTG 
ACAG AAA CCA GG- 3’; probe 2: 5’-TTG ACA GAA ACC AGG TGC CTT CAG AGG 
CTC TCT GAT TTA AAT AAA CCT TTC TTG TTT- 3’), which hybridize to the 3’ 
untranslated region of the human ENT1 gene, were utilized in the microarray chip to detect 
the ENT1 transcript. Of note, probe 2 also maps to another location in chromosome 13, 
based on a default “human BLAT search” available at http://moma.ki.au.dk/genome-mirror/
cgi-bin/hgBlat. ENT1 expression levels in the postmortem frontal cortex were studied in 
both control and HD groups and further grouped by their Vonsattel neuropathologicalal 
severity score, which consists of five stages of progression of striatal abnormalities, which 
correlate with the degree of clinical symptoms: grade 0, clinical evidence but no 
pathological abnormalities; grade 1, minimal microscopic abnormalities (neuronal loss and 
astrocytosis) with no macroscopic abnormalities (reduced striatal volume, atrophy); grade 2, 
more pronounced microscopic abnormalities and minimal macroscopic abnormalities; grade 
3 and 4, severe and very severe microscopic and macroscopic abnormalities (Vonsattel et al., 
1985).
Differential coexpression analysis
Differential coexpression (DC) was tested using a self-contained test (Narayanan et al., 
2014), which inspects if a gene of interest (SLC29A1 in our case) shows DC patterns 
between HD versus control samples on their own right, without reference to any other genes 
in the genome. This is done by collecting all partner genes correlated to a “hub” gene of 
interest (like SLC29A1) in either the HD or controls group, and testing if the median change 
in correlation strength between the hub gene and the partner genes are beyond sampling 
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noise estimated from bootstrap resampling. Specifically, to compute the bootstrap-based p-
value, we bootstrap resample the HD dataset 1000 times and Control dataset 1000 times and 
compute how often the median change in correlation between a hub gene and all other 
partner genes (specifically difference of Fisher-Z transformed Spearman correlation 
coefficient in HD and Control groups) happen in the resampled datasets. This test served as 
an additional confirmation of the SLC29A1 hub seen in the overall HD versus control DC 
network controlled at FDR 1%.
Results
Unaltered A2AR agonist-mediated psychomotor depression and A2AR antagonist binding 
properties in Tg51 rats
Previous results of experiments in Tg51 rats showed the inability of the selective A2AR 
antagonist KW-6002 to increase locomotor activity at 6 and 12, but not at 3 months of age 
(Orrú et al., 2011). These results were interpreted as an alteration in the density (decrease) or 
function of striatal A2AR at still early neuropathological stages of this HD animal model. In 
that case we would also expect differences in the psychomotor depressant effects of an 
A2AR agonist, such as CGS-21680. In fact, both the psychomotor activating effects of 
KW-6002 and depressant effects of CGS-21680 depend on the integrity of the striatal A2AR, 
as they are eliminated in A2AR KO mice (Chen et al., 2001; Yu et al., 2008). CGS 21680 
(0.03 and 0.1 mg/kg, i.p.) produced a depressant effect in 3- and 12-month old Tg51, both 
for heterozygous (HET) and homozygous (HOM), as compared to WT littermates (Fig. 1). 
As shown in Fig. 1, there was an apparent increase in locomotor activity with vehicle 
administration in Tg51 rats as compared with WT. Nevertheless, both for 3-month and 12-
month old rats, a bifactorial ANOVA showed a very significant effect of CGS-21680 
(p<0.0001 in both cases) without significant genotype effect or CGS-21680-genotype 
interaction. Furthermore, comparison of the binding properties of the A2AR antagonist 
[3H]ZM-241385 in striatal preparations of 3- and 12-month old HET and HOM Tg51 and 
WT controls did not show any significant differences in affinity (KD) or number of binding 
sites (Bmax) based on ANOVA followed by Dunnett’s post hoc test (Table 1). These 
behavioral and biochemical results indicated unimpaired striatal A2AR density or function in 
Tg51 rats.
Low striatal extracellular levels of adenosine in Tg51 rats and zQ175 mice
A low adenosine tone could explain the existence of an impairment of the pharmacological 
effects of an A2AR antagonist without a concomitant impairment of the A2AR density or 
function. In fact, both in HOM and HET 12-month old Tg51 rats, the striatal levels of 
adenosine, measured by in vivo microdialysis, were significantly lower as compared with 
WT littermates (Fig. 2A). No significant differences were observed between the different 
genotype groups at 3 months of age. We then tested for striatal adenosine levels in the 
zQ175 knock-in mouse, recently developed by Menalled and colleagues in an attempt to 
have the HTT gene in a context that causes a phenotype more closely mimicking HD in 
humans (Menalled et al., 2012). In fact, behavioral, electrophysiological, histological, 
biochemical and imaging data indicate that the progressive phenotypes of both HOM and 
HET zQ175 mice up to 12 months of age recapitulate better the early phenotypic stages of 
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HD than previous animal models (Menalled et a., 2012; Heikkinen et al., 2012; Peng et al., 
2016). HET zqQ175 mice were chosen for the present study since they provide a more 
insidious and less penetrating genotype than HOM (Peng et al., 2016) and similar 
neuropathological changes than the 12-month old hetero- and homozygous Tg51 rats 
(Kántor et al., 2006; Heikkinen et al., 2012), which correspond to grade 2 in the Vonsattel 
neuropathological severity score in patients with HD (see above).The results confirmed 
those obtained with Tg51 rats and zQ175 mice showed striatal extracellular levels of 
adenosine that were significantly lower than for WT littermates (Fig. 2B).
High striatal density of ENT1 and low striatal density of A2AR antagonist binding sites in 
zQ175 mice
In view of the crucial role of ENT1 in determining the extracellular content of adenosine in 
the brain, we investigated the possibility of an ENT1 upregulation in the striatum of zQ175 
mice, performing saturation experiments of the ENT1 inhibitor [3H]NBTI. In fact, the 
striatal binding of the ENT1 inhibitor [3H]NBTI was increased in zQ175 mice as compared 
to WT littermates (Figs. 3A and 3B), with a significant increase in the number of binding 
sites (Bmax: 0.35 ± 0.02 pmol/mg protein versus 0.27 ± 0.03 pmol/mg of protein) and no 
significant change in affinity (KD: 0.11 ± 0.03 versus 0.11 ± 0.01 nM). The striatal density 
of A2AR was also analyzed with saturation experiments with [3H]ZM-241385. The binding 
of the A2AR antagonist was decreased in zQ175 mice as compared to WT littermates (Figs. 
3C and 3D), with a significant decrease in the number of binding sites (Bmax: 0.30 ± 0.04 
pmol/mg protein versus 0.62 ± 0.07 pmol/mg of protein) and no significant change in 
affinity (KD: 0.50 ± 0.08 versus 0.49 ± 0.08 nM).
Increased expression of the ENT1 transcript in HD
If zQ175 mice do represent a valid model of the HD, we could expect an upregulation of 
ENT1 in postmortem brain tissue from patients with less severe neuropathological stages of 
HD. Analysis of the relative level of ENT1 transcript (SLC29A1) in the postmortem 
prefrontal cortex of 157 non-HD subjects and 127 HD patients with different 
neuropathological severity of the disease was performed using two different probes, as 
detailed in the Methods section. Data analysis revealed that HD patients with Vonsattel 
severity score 2, but not those with higher severity stage 3 or 4, expressed significantly 
higher levels of ENT1 transcript than non-HD subjects (Fig. 4).
In addition to comparing the average expression level of SLC29A1 in the HD versus the 
control group (in differential expression analysis), we also inspected if the coordinate 
regulation of SLC29A1 with other genes in the genome were disrupted (gained/lost) in the 
HD group relative to controls. Several recent studies have utilized DC analysis to identify 
disease-dysregulated genes that are complementary to signature genes found in a DE 
analysis (Narayanan et al., 2011), since the correlation among two genes across individuals 
could be gained or lost in the disease group relative to controls without any significant 
change in their mean expression level across the two groups. We took the network of 
previously published DC relations identified at FDR 1% in this cohort of HD versus control 
individuals and extracted those DC relations that involved SLC29A1. This subnetwork 
revealed that the gene for ENT1 (SLC29A1) exhibited differential correlations (mostly gain 
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of correlations) to at least 60 other gene reporters in HD patients relative to controls 
suggesting that it serves as a hub of HD-induced dysregulation (Fig. 5; P<1/1000 in 
bootstrap-based test; see Methods). This hub-like DC pattern appears to be reflective of the 
drastic rewiring of the entire gene-gene coexpression network observed when comparing HD 
versus control groups (Narayanan et al., 2014). The genes that SCL29A1 was differentially 
correlated with between the HD versus controls groups were enriched for protein folding 
annotations at p<0.05 (Bonferroni-corrected p value computed through PANTHER over-
representation test, available at pantherdb.org and released 2016-07-15, for GO-Slim 
Biological Process terms in PANTHER version 11.0, released 2016-07-15). Amongst these 
DC partner genes of SLC29A1, the ones annotated with protein folding or chaperone related 
functions included PTGES3, HSPD1, HSP90AA5P, FKBP4, SUGT1, and STIP1. 
Importantly, the role of autophagy mediated by chaperones such as Hsp90 proteins in the 
clearance of Htt has been previously described (Qi and Zhang, 2014).
Discussion
The role of adenosine receptors in the pathogenesis of HD has been the focus of intense 
research. Preclinical, clinical and genetic studies strongly point to a particularly important 
role of A2AR, and downregulation of A2AR has been consistently reported in HD rodent 
models and also in early stages of the disease (see Introduction and Lee and Chern, 2014). It 
was therefore surprising that our experiments in transgenic HD Tg51 rats did not show any 
evidence for a change in the number of A2AR antagonist binding sites, while in a previous 
report we had shown that HD Tg51 rats were insensitive to the locomotor activating effects 
of an A2AR antagonist (Orrú et al., 2011). Since the analysis of locomotor depression 
induced by an A2AR agonist also indicated no evidence for A2AR functional abnormalities, 
it became obvious to investigate a reduction in the striatal adenosine tone. In fact, the striatal 
extracellular concentration of adenosine was significantly reduced in Tg51 rats and also in 
the recently introduced animal model of HD, the zQ175 knock-in mouse (Heikkinen et al., 
2012; Menalled et al., 2012). A2AR antagonist binding was nevertheless found to be 
significantly reduced in zQ175 mice, even though both rodent models were analyzed at ages 
that show a similar neuropathological degree, which correspond to early neuropathological 
stages of HD (grade 2 in the Vonsattel scale). This suggests that reduced adenosine (evident 
in both models) and reduced A2AR density (only evident in zQ175 mice) are two 
independent processes that develop during the initial neuropathological stages of the disease.
Brain adenosine homeostasis is under the control of several transporters and enzymes. 
Evidence has been accumulating indicating the involvement of adenosine and astroglia in 
HD (Lee and Chern, 2014). Adenosine may be released as such from cells (Melani et al., 
2012) or may be a product of ATP that is released mostly by astrocytes and is transformed 
into adenosine by means of membrane-associated ecto-5’-nucleotidases (CD39 and CD73) 
(Boison et al., 2010). Extracellular adenosine removal depends mostly on the uptake via the 
equilibrative nucleoside transporter ENT1 (Li et al., 2013), also predominantly expressed in 
astrocytes (Peng, 2005; Wu et al., 2010). Upregulation of ENT1 should lead to reduced 
adenosine tone, a mechanism that has been invoked to be involved in the pathogenesis of 
several neuropsychiatric disorders, including alcohol use disorder and depression (Prediger 
et al., 2006; Gass et al., 2010; Sari et al., 2013; Hines and Haydon, 2014). We therefore 
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sought for an upregulation of ENT1 in HD rodent models. Indeed, we did not only found the 
striatal density of ENT1 expression significantly increased in the zQ175 knock-in mouse, 
but the expression of the ENT1 transcript (SLC29A1) was significantly increased in 
postmortem prefrontal cortex from HD patients with a grade 2 Vonsattel severity score. The 
difference in SLC29A1 expression was not seen in more severe neuropathological stages 
(Vonsattel severity score 3 and 4). The demonstration of the same biochemical changes in 
equivalent neuropathological stages in the rodent model and HD patients strongly supports 
ENT1 as a biomarker for HD. Furthermore, a differential coexpression analysis 
demonstrated that SLC29A1 serves as a critical hub of HD-induced gene dysregulation. 
These results underscore a significant pathogenetic role of ENT1, especially considering that 
our DC analysis showed ENT1 gained correlations to several other genes in the HD group 
comprising all HD stage samples relative to controls.
Altogether, the present study demonstrates that ENT1 and striatal extracellular adenosine 
constitute biomarkers of the initial stages of neurodegeneration in HD. It is well established 
that adenosine plays an important neuroprotective role (Stone et al., 2009; Ribeiro et al., 
2016) and evidence has been accumulating indicating the involvement of adenosine and 
astroglia in HD (Lee and Chern, 2014). As mentioned in the Introduction, an insufficient 
tonic activation of A2AR, which can be related to decreased levels of both the 
neurotransmitter and the receptor, can be involved in the previously described impairment of 
BDNF-neuroprotective effect in HD (Zuccato et al., 2001; Lee and Chern, 2014). But altered 
expression and function of the adenosine receptor (A1R) has also recently reported in mice 
and patients with HD (Ferrante et al., 2014; Matusch et al., 2014). The potential impact of 
lower adenosine tone on the function of dysregulated A1R (Blum et al., 2002; Ferrante et al., 
2014) during HD progression warrants further investigation.
Therefore, reduced extracellular levels of adenosine secondary to ENT-1 upregulation can be 
fundamental in the progression of the disease and most probably contributes to the reduced 
age of onset of HD associated with an A2AR polymorphism and with caffeine intake 
(Dhaenens et al., 2009; Taherzadeh-Fard et al., 2010). Collectively, these findings predict 
that ENT1 could constitute a new therapeutic target and ENT1 blockers, such as 
dipyridamole and T1–11 (Huang et al., 2011), could at least delay the age of onset of HD.
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* Decrease in striatal extracellular levels of adenosine was found in HD 
rodent models
* This was paralleled by upregulation of the equilibrative nucleoside 
transporter ENT1
* ENT1 was also demonstrated in postmortem brain tissue from HD patients
* Adenosine and ENT1 can constitute biomarkers an therapeutic targets for 
HD
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Locomotor depression induced by the A2AR agonist CGS-21680 (0.03 and 0.1 mg/kg, i.p.) 
in homozygous (HOM) and heterozygous (HET) Tg51 rats and wild-type littermates WT 
measured at 3 and 12 months of age. Values represent means ± S.E.M. (n = 6–8 per group) 
of the average of 10-min period transformed counts (square root) during the 90-min period 
of observation. * and **: significantly different compared to vehicle-treated rats (VEH); 
p<0.05 and p<0.01, respectively; Bifactorial ANOVA, followed by one-way ANOVA with 
Dunnett’s post hoc test.
Guitart et al. Page 14














Basal striatal levels of adenosine as measured with in vivo microdialysis in homozygous 
(HOM) and heterozygous (HET) Tg51 rats measured at 3 and 12 months of age (A) and in 
heterozygous 12 month-old zQ175 knock-in mice (B) at 12 months of age as compared with 
wild-type littermates (WT). Results are expressed as means ± S.E.M. (n = 6–8 per group) of 
the concentration of adenosine (µM). * and **: significantly different compared to WT; 
p<0.05 and p<0.01, respectively; ANOVA with Dunnett’s post hoc test or non-paired 
Student’s t test.
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Binding of ENT1 and A2AR ligands in the striatum of zQ175 mice wild-type littermates 
(WT). A. Representative saturation curves of the ENT1 ligand [3H]NBTI. B. Bmax values of 
[3H]NBTI binding; results are expressed as means ± S.E.M. (n = 8–10 per group). C. 
Representative saturation curves of the A2AR ligand [3H]ZM-241385. D. Bmax values of 
[3H]ZM-241385 binding; results are expressed as means ± S.E.M. (n = 5 per group). *: 
significantly different compared to WT; p< 0.01; unpaired Student’s t test.
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ENT1 transcript expression in HD patients. The relative expression of the ENT1 gene 
(SLC29A1) from the prefrontal cortex of 157 non-demented controls and 127 HD patients 
derived from gene expression data of a previous study and two different probes were used 
(see Methods). Disease severity was determined based on Vonsattel staging as mild/
moderate (Stage 2; n = 38) or severe (Stage 3; n = 59; Stage 4, n = 30). Values represent 
means ± S.E.M.; * and **: significantly different as compared to controls; * and **: 
significantly different compared to WT; p<0.05 and p<0.01, respectively; ANOVA with 
Dunnett’s post hoc test.
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Altered coexpression pattern of the ENT1 transcript SLC29A1 in HD patients versus 
controls. The graph shows all genes differentially coexpressed with SLC29A1 in HD versus 
controls individuals, as chosen from the HD versus controls DC network identified at FDR 
1% in a previously published study (see text). SLC29A1 acts as a hub that is dysregulated 
with many other genes; red edges indicate gain of correlation between the gene pair in 
disease, and green edges are loss of correlation.
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